Investor Presentaiton

R&D investor presentation Early RybelsusⓇ uptake further supports GLP-1 NBRX and TRX market leadership in the US Weekly NBRX share 70% 60% 50% 40% 30% 20% 10% 0% Apr 2019 USA GLP-1 TRX market size and market share USA GLP-1 NBRx market share NN GLP-1 - OzempicⓇ dulaglutide RybelsusⓇ VictozaⓇ TRX volume (million) 2.0 57.3% 1.5 36.2% 1.0 35.7% Source: NBRX-IQVIA Xponent, week ending 29 May 2020 NBRX: New-to-brand prescriptions 13.4% 0.5 8.2% 0.0 May 2020 Apr 2019 - NN GLP-1 - 7 OzempicⓇ dulaglutide - RybelsusⓇ VictozaⓇ TRX share Source: TRX volume is based on monthly data through April 2020; TBRX-IQVIA Xponent, week ending 29 May 2020 TRX: Total prescriptions 60% 48.3% 50% 44.6% 40% 30% 24.9% 20% 21.3% 10% 2.1% 0% May 2020 novo nordisk

View entire presentation